Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Driehaus Capital Management LLC

Driehaus Capital Management LLC lessened its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 16.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 613,550 shares of the company's stock after selling 117,393 shares during the quarter. Driehaus Capital Management LLC owned about 0.85% of Kiniksa Pharmaceuticals worth $12,136,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Braidwell LP boosted its position in shares of Kiniksa Pharmaceuticals by 19.3% during the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company's stock worth $68,289,000 after purchasing an additional 557,934 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Kiniksa Pharmaceuticals by 3.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock worth $15,262,000 after buying an additional 29,300 shares during the period. Geode Capital Management LLC boosted its position in shares of Kiniksa Pharmaceuticals by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 492,630 shares of the company's stock worth $9,744,000 after buying an additional 9,654 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Kiniksa Pharmaceuticals by 138.9% in the fourth quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company's stock valued at $9,451,000 after buying an additional 277,827 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Kiniksa Pharmaceuticals by 11.1% in the 4th quarter. Northern Trust Corp now owns 283,599 shares of the company's stock valued at $5,610,000 after buying an additional 28,393 shares during the period. Hedge funds and other institutional investors own 53.95% of the company's stock.

Insider Transactions at Kiniksa Pharmaceuticals

In other news, CAO Michael R. Megna sold 9,051 shares of Kiniksa Pharmaceuticals stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total value of $203,194.95. Following the sale, the chief accounting officer now owns 26,528 shares of the company's stock, valued at $595,553.60. The trade was a 25.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ross Moat sold 6,272 shares of the firm's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $28.00, for a total value of $175,616.00. Following the completion of the sale, the insider now directly owns 9,415 shares of the company's stock, valued at approximately $263,620. This trade represents a 39.98% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 228,768 shares of company stock valued at $5,591,506. Corporate insiders own 54.57% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on KNSA. Wedbush reaffirmed an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Jefferies Financial Group upped their target price on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Finally, Citigroup assumed coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a "buy" rating and a $40.00 target price on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $38.80.

Kiniksa Pharmaceuticals Trading Down 4.6%

NASDAQ:KNSA traded down $1.24 during mid-day trading on Tuesday, hitting $25.60. The stock had a trading volume of 414,215 shares, compared to its average volume of 481,429. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $17.38 and a twelve month high of $28.56. The stock has a 50-day simple moving average of $22.51 and a two-hundred day simple moving average of $21.29. The company has a market capitalization of $1.86 billion, a PE ratio of -182.84 and a beta of 0.07.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.09. The business had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company's revenue was up 72.5% on a year-over-year basis. During the same period last year, the business earned ($0.25) EPS. Sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.